Malnutrition in Chronic Gastrointestinal Diseases, Cross-sectional Study

NCT ID: NCT04474743

Last Updated: 2021-11-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

345 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-02

Study Completion Date

2021-09-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Malnutrition and muscle wasting are common consequences of life-threatening, chronic diseases of the gastrointestinal tract. Such diseases include liver cirrhosis, chronic pancreatitis and short bowel syndrome. Malnutrition and muscle wasting increase the risk of complications, reduce the life expectancy and impair the quality of life. The development of malnutrition and muscle wasting is different, as is the diagnosis and nutritional treatment. There are also different mechanisms of origin for the underlying diseases. The aim of the study is to compare data related to nutrition and physical condition of patients with liver cirrhosis, chronic pancreatitis and short bowel syndrome. Malnutrition and muscle wasting within the specific diseases will be characterized and possible correlations will be identified.

For this, malnourished and non-malnourished patients of the different diseases are compared with controls patients with non-specific complaints of the gastrointestinal tract as well as with healthy study participants.

Data on food intake, physical activity, body composition and body measurements as well as muscle strength and muscle function are recorded. Blood values as well as transport and barrier properties of the intestine will also be examined.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Malnutrition and sarcopenia are consequences of life-threatening gastroenterological diseases such as liver cirrhosis, chronic pancreatitis and short bowel syndrome and are associated with a poorer clinical outcome and a reduced quality of life. The diagnostic criteria of both conditions differ, as do the consequences for adequate nutritional therapy. Nevertheless, malnutrition and sarcopenia are often discussed in confusion in the literature. In addition, the underlying mechanisms of malnutrition and sarcopenia can differ in the various diseases. The aim of the study is to compare nutrition-associated parameters from patients with liver cirrhosis, chronic pancreatitis and short bowel syndrome, to characterize the disease-specific phenotype of malnutrition and sarcopenia of the examined diseases and to obtain information on mechanistic relationships. The pathophysiological understanding of the clinical settings as well as the development of malnutrition and sarcopenia is important for choosing specific nutritional therapies. For this, malnourished and non-malnourished patients of each examined disease are compared with controls from patients with non-specific, abdominal symptoms and healthy control subjects. Data on food intake, physical activity, body composition and anthropometry as well as muscle strength and muscle function are recorded. Clinical and chemical blood parameters, the plasma metabolome as well as transport and barrier proteins of the intestine are also examined.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cirrhoses Chronic Pancreatitis Short Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Liver Cirrhosis

Patients diagnosed with liver cirrhosis.

No intervention - cross-sectional observational only

Intervention Type OTHER

No intervention - cross-sectional observational only

Chronic Pancreatitis

Patients diagnosed with chronic pancreatitis.

No intervention - cross-sectional observational only

Intervention Type OTHER

No intervention - cross-sectional observational only

Short Bowel Syndrome

Patients diagnosed with short bowel Syndrome.

No intervention - cross-sectional observational only

Intervention Type OTHER

No intervention - cross-sectional observational only

Control Patients

Otherwise healthy patients visiting hospital with other non-severe diseases.

No intervention - cross-sectional observational only

Intervention Type OTHER

No intervention - cross-sectional observational only

Healthy Controls

Healthy subjects recruited from the general population.

No intervention - cross-sectional observational only

Intervention Type OTHER

No intervention - cross-sectional observational only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention - cross-sectional observational only

No intervention - cross-sectional observational only

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Liver Cirrhosis:

* based on clinical and imaging criteria (sonography or computed tomography (CT) or magnetic resonance imaging (MRI)) without evidence of hepatocellular carcinoma
* Child-Pugh Stadium A-C

Chronic Pancreatitis:

* based on imaging criteria (endoscopic ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance cholangiopancreatography (MRCP))
* large and small duct disease
* with or without exocrine insufficiency
* with or without endocrine insufficiency
* patients after left pancreatic resection or pancreaticojejunostomy or duodenal pancreatic head resection

Short Bowel Syndrome (SBS):

\- based on clinical anamnestic criteria and state after bowel resection followed by primary or secondary oral autonomy (intestinal failure)

Control Patients:

* patients without known underlying gastroenterological disease with an indication for esophago-gastro-duodenoscopy for symptom clarification
* negative Nutritional Risk Screening (NRS-2002 \< 3)
* gastroscopy without clinically relevant result (mild gastritis aspect, small axial hernia, typical glandular cysts, typical brunneromas can be included)
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria

* parenteral nutrition in the previous 6 months
* pacemaker or implanted defibrillator
* pregnancy or lactation
* lack of ability to answer the questionnaires
* taking certain medications during the previous 4 weeks (protein pump inhibitors and H2 antagonists, except medication on demand or ≤ 4 weeks continuously, antibiotics, narcotics, non-opioid analgesics except medication on demand (≤ 1 day/week), anticholinergics, antidepressants, motility drugs (metoclopramide, motilium, bromocriptine, prucalopride), thyroid drugs except stable thyroid hormone substitution with euthyroid metabolism, steroids, immunomodulators, anti-inflammatory biologics)

Subsequent Exclusion of Control Patients:

* if, contrary to expectations, malnutrition is diagnosed in spite of an inconspicuous NRS-2002 within the framework of the study
* as well as in the case of relevant, conspicuous esophago-gastro-duodenoscopy findings


Liver Cirrhosis:

* steatohepatitis according to clinical or laboratory parameters
* acute alcoholic hepatitis according to clinical and imaging parameters (sonography, CT, MRI)
* existing transjugular intrahepatic portosystemic shunt (TIPS)
* known hepatocellular carcinoma (HCC)
* state after liver transplantation

Chronic Pancreatitis:

* acute pancreatitis
* extrapancreatic infection
* coexisting liver cirrhosis based on clinical and imaging parameters
* state after surgery with alteration of food flow (partial or total pancreaticoduodenectomy)
* known pancreatic carcinoma or state after therapy of pancreatic carcinoma (surgery or chemotherapy or radiation)

Short Bowel Syndrome (SBS):

* acute phase of intestinal insufficiency (less than 28 days after resection)
* intravenous substitution of macronutrients (water, electrolytes, glucose, amino acids or lipids (intestinal insufficiency)
* intramuscular substitution of micronutrients is allowed (e.g. vitamin B12)
* uncontrolled underlying disease leading to SBS (e.g. active Crohn's disease)

Control Patients:

* major underlying and concomitant diseases
* food allergies

Healthy controls:

* tumor diseases in the past 5 years
* medically diagnosed, serious chronic diseases or changes in the gastrointestinal tract that may affect the absorption of nutrients (e.g. celiac disease, chronic inflammatory bowel disease or irritable bowel syndrome diagnosed according to Rome IV criteria, relevant bowel resections including short bowel syndrome)
* rheumatic diseases requiring permanent drug therapy (rheumatoid arthritis, fibromyalgia)
* chronic use of anti-inflammatory or pain-relieving drugs or use of anti-inflammatory or pain-relieving drugs for more than 3 days in the last 3 weeks
* average daily alcohol consumption \> 20 g in women and \> 30 g in men
* diagnosed severe liver disease requiring medical attention and drug therapy (liver cirrhosis, non-alcoholic steatohepatitis (NASH) / alcoholic steatohepatitis (ASH), hepatitides)
* acute or chronic pancreatitis
* acute and chronic renal failure
* myocardial infarction or cerebral insult within 6 months prior to examination
* coronary artery disease/pAVK (peripheral artery disease (PAD))
* heart failure with stages 3 and 4 according to NYHA (New York Heart Association) classification
* severe chronic pulmonary disease (COPD)
* history of significant neurological or psychiatric diseases (including epilepsy, bipolar disorders, dementia and neuromuscular diseases)
* presence of pareses including mono- and diparesis
* rare congenital metabolic diseases (cystic fibrosis, phenylketonuria)
* expected altered body composition (extreme sports activity \< 2h/day), edema, amputation of the extremities (arm and/or leg)
* highly atypical or restrictive dietary choices/concepts followed voluntarily (macrobiotics, paleo-diet, Atkins diet, Mayo diet, instinctive diets) or due to food intolerances/allergies
* simultaneous participation in other studies associated with drug use and potentially having a significant impact on body composition or dietary behaviour
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Medical Center Rostock

OTHER

Sponsor Role collaborator

University of Applied Sciences Neubrandenburg

OTHER

Sponsor Role collaborator

Leibniz Institute for Farm Animal Biology (FBN)

UNKNOWN

Sponsor Role collaborator

University Medicine Greifswald

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Prof. Dr. med. Lamprecht

Role: PRINCIPAL_INVESTIGATOR

University Medicine Rostock

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Medicine Greifswald

Greifswald, , Germany

Site Status

University of Applied Sciences Neubrandenburg

Neubrandenburg, , Germany

Site Status

Univeristy Medicine Rostock

Rostock, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Wiese ML, Gartner S, von Essen N, Doller J, Frost F, Tran QT, Weiss FU, Meyer F, Valentini L, Garbe LA, Metges CC, Bannert K, Sautter LF, Ehlers L, Jaster R, Lamprecht G, Steveling A, Lerch MM, Aghdassi AA. Malnutrition Is Highly Prevalent in Patients With Chronic Pancreatitis and Characterized by Loss of Skeletal Muscle Mass but Absence of Impaired Physical Function. Front Nutr. 2022 Jun 1;9:889489. doi: 10.3389/fnut.2022.889489. eCollection 2022.

Reference Type DERIVED
PMID: 35719155 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A 2018-0129

Identifier Type: -

Identifier Source: org_study_id